< Back to latest news & events

HGF Presents

Personalised Medicine Patenting of Known Drugs for Known Indications at the EPO

September 2025

Video overview:

The identification of specific sub-groups of patients to treat with a known drug, even if said patients may have been treated before with the drug, can yield patentable subject matter under the European Patent Convention.

In this episode of HGF Presents, Laurence identifies the key case law that supports the ability to secure patent protection for known drugs for use in treating a known disease, but wherein the patient to be treated is purposefully selected based on a biomarker that, e.g., distinguishes responders from non-responders.

Latest updates

The Bite of Implied Consent: Lessons from the Pink Lady Case

A recent European Union court decision considers the issue of implied consent to commercialise a plant variety, and whether the evidence meets the threshold of “serious doubts” of the validity …

Read article
Event - 5th November 2025

HGF are Gold Sponsors of IAM Live: Navigating the UPC 2025

We’re excited to share that HGF is a Gold Sponsor of IAM Live: Navigating the UPC 2025, taking place on the 5th November at the Marriott Opera Ambassador Hotel in …

Event details

HGF ranked band 1 in Chambers and Partners UK 2026

The Chambers and Partners UK 2026 Guide is now live and HGF has one again been highly ranked as a firm, with several recognised individuals across multiple regions. HGF is …

Read article

How France's investment in digital health, AI, and bioinformatics is transforming the intellectual property (IP) landscape

In recent years, France has become a key player in digital health innovation, driven by strategic government investments under the France 2030 initiative and the French Tech 2030 program. These …

Read article
Event - 14th October 2025

The Future of Protein Production Amsterdam 2025

HGF are proud to be sponsoring the Future of Protein Production Amsterdam 2025, the leading global event bringing together innovators across fermentation, cultivated and plant-based proteins. Date: 29-30th October 2025  …

Event details

A Turning Point for AI Patent Eligibility?

Director Squires Vacates PTAB § 101 Rejection in DeepMind Case In a notable early move as Under Secretary of Commerce and USPTO Director, John Squires has vacated a Patent Trial …

Read article

T 0792/24: Novelty and Inventiveness of Second Medical Use Claims

The EPO Board of Appeal’s decision in T 0792/24 provides helpful guidance on the assessment of novelty and inventive step for European second medical use claims. In light of a …

Read article

HGF Highly Ranked in Legal 500 2026

The Legal 500 UK 2026 rankings have been released and HGF has once again been ranked across several regions and practice areas. HGF continue to be ranked in the Top-Tier …

Read article